236 related articles for article (PubMed ID: 25956075)
41. Characterization of Medication Velocity and Size Distribution from Pressurized Metered-Dose Inhalers by Phase Doppler Anemometry.
Alatrash A; Matida E
J Aerosol Med Pulm Drug Deliv; 2016 Dec; 29(6):501-513. PubMed ID: 27504720
[TBL] [Abstract][Full Text] [Related]
42. Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro.
Haghi M; Bebawy M; Colombo P; Forbes B; Lewis DA; Salama R; Traini D; Young PM
Eur J Pharm Biopharm; 2014 Jan; 86(1):38-45. PubMed ID: 23528797
[TBL] [Abstract][Full Text] [Related]
43. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers.
Ganderton D; Lewis D; Davies R; Meakin B; Brambilla G; Church T
Respir Med; 2002 Aug; 96 Suppl D():S3-8. PubMed ID: 12201079
[TBL] [Abstract][Full Text] [Related]
44. Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence.
Aggarwal B; Gogtay J
Expert Rev Respir Med; 2014 Jun; 8(3):349-56. PubMed ID: 24802511
[TBL] [Abstract][Full Text] [Related]
45. Novel simvastatin inhalation formulation and characterisation.
Tulbah AS; Ong HX; Colombo P; Young PM; Traini D
AAPS PharmSciTech; 2014 Aug; 15(4):956-62. PubMed ID: 24806822
[TBL] [Abstract][Full Text] [Related]
46. Nonuniform Deposition of Pressurized Metered-Dose Aerosol in Spacer Devices.
Ogrodnik N; Azzi V; Sprigge E; Fiset S; Matida E
J Aerosol Med Pulm Drug Deliv; 2016 Dec; 29(6):490-500. PubMed ID: 27224033
[TBL] [Abstract][Full Text] [Related]
47. Discriminating Ability of Abbreviated Impactor Measurement Approach (AIM) to Detect Changes in Mass Median Aerodynamic Diameter (MMAD) of an Albuterol/Salbutamol pMDI Aerosol.
David Christopher J; Patel RB; Mitchell JP; Tougas TP; Goodey AP; Quiroz J; Andersson PU; Lyapustina S
AAPS PharmSciTech; 2017 Nov; 18(8):3296-3306. PubMed ID: 28589305
[TBL] [Abstract][Full Text] [Related]
48. Comparative in vitro performance of three small-volume valved holding chambers with beclomethasone/formoterol pressurized metered dose inhaler.
Goncalves TM; Alhanout K; Nicolay A; Dubus JC; de Santana DP; Andrieu V
J Aerosol Med Pulm Drug Deliv; 2013 Aug; 26(4):223-7. PubMed ID: 23094686
[TBL] [Abstract][Full Text] [Related]
49. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology.
Taylor G; Warren S; Dwivedi S; Sommerville M; Mello L; Orevillo C; Maes A; Martin UJ; Usmani OS
Eur J Pharm Sci; 2018 Jan; 111():450-457. PubMed ID: 29055732
[TBL] [Abstract][Full Text] [Related]
50. Impact of droplet evaporation rate on resulting in vitro performance parameters of pressurized metered dose inhalers.
Sheth P; Grimes MR; Stein SW; Myrdal PB
Int J Pharm; 2017 Aug; 528(1-2):360-371. PubMed ID: 28599855
[TBL] [Abstract][Full Text] [Related]
51. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
Hein S; Bur M; Schaefer UF; Lehr CM
Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
[TBL] [Abstract][Full Text] [Related]
52. Respiratory Tract Deposition of HFA-Beclomethasone and HFA-Fluticasone in Asthmatic Patients.
Leach CL; Kuehl PJ; Chand R; McDonald JD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):127-33. PubMed ID: 26061801
[TBL] [Abstract][Full Text] [Related]
53. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy.
Onoue S; Misaka S; Kawabata Y; Yamada S
Expert Opin Drug Deliv; 2009 Aug; 6(8):793-811. PubMed ID: 19558334
[TBL] [Abstract][Full Text] [Related]
54. Inhaler usability of a pressurized metered dose inhaler and a soft mist inhaler in patients with COPD: A simulated-use study.
Ding B; Siddiqui S; DePietro M; Petersson G; Martin UJ
Chron Respir Dis; 2019; 16():1479972318787914. PubMed ID: 30016880
[TBL] [Abstract][Full Text] [Related]
55. Novel pMDI formulations for pulmonary delivery of proteins.
Li HY; Seville PC
Int J Pharm; 2010 Jan; 385(1-2):73-8. PubMed ID: 19854252
[TBL] [Abstract][Full Text] [Related]
56. Oronasal and Tracheostomy Delivery of Soft Mist and Pressurized Metered-Dose Inhalers With Valved Holding Chamber.
Berlinski A; Cooper B
Respir Care; 2016 Jul; 61(7):913-9. PubMed ID: 27006348
[TBL] [Abstract][Full Text] [Related]
57. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
58. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
59. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica.
Cheng YS; Fu CS; Yazzie D; Zhou Y
J Aerosol Med; 2001; 14(2):255-66. PubMed ID: 11681657
[TBL] [Abstract][Full Text] [Related]
60. Plume Characteristics of Two HFA-Driven Inhaled Corticosteroid/Long-Acting Beta2-Agonist Combination Pressurized Metered-Dose Inhalers.
Johal B; Murphy S; Tuohy J; Marshall J
Adv Ther; 2015 Jun; 32(6):567-79. PubMed ID: 26100350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
